Effect of rosuvastatin on hemoglobin levels in patients with anemia and low-grade inflammation: A post hoc analysis of the JUPITER trial

Journal of Clinical Pharmacology

Volumn 51, Issue 10, 2011, Pages 1483-1487

  Brookhart, M Alan ^a,b   Solomon, Daniel H ^a   Glynn, Robert J ^a   Ridker, Paul M ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b IL   (United States)

Author keywords

Anemia; hepcidin; hsCRP; inflammation

Indexed keywords

HEMOGLOBIN; ROSUVASTATIN;

ADULT; AGED; ANEMIA; ARTICLE; CARDIOVASCULAR DISEASE; DRUG EFFECT; FEMALE; HEMOGLOBIN BLOOD LEVEL; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; POST HOC ANALYSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC);

AGED; ANEMIA; DOUBLE-BLIND METHOD; FEMALE; FLUOROBENZENES; HEMOGLOBINS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INFLAMMATION; MALE; MIDDLE AGED; PYRIMIDINES; SULFONAMIDES;

EID: 80053290040     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270010386607     Document Type: Article

References (21)

1. Guralnik JM, Eisenstaedt RS, Ferrucci L, Klein HG, Woodman RC. Prevalence of anemia in persons 65 years and older in the United States: evidence for a high rate of unexplained anemia. Blood. 2004 ; 104: 2263-2268 (Pubitemid 39331821)
2. Weiss G, Goodnough LT. Anemia of chronic disease. N Engl J Med. 2005 ; 352: 1011-1023
3. Nicolas G, Chauvet C, Viatte L, et al. The gene encoding the iron regulatory peptide hepcidin is regulated by anemia, hypoxia, and inflammation. J Clin Invest. 2002 ; 110: 1037-1044
4. Muckenthaler M, Roy CN, Custodio AO, et al. Regulatory defects in liver and intestine implicate abnormal hepcidin and Cybrd1 expression in mouse hemochromatosis. Nat Genet. 2003 ; 34: 102-107 (Pubitemid 36548799)
5. Theurl I, Aigner E, Theurl M, et al. Regulation of iron homeostasis in anemia of chronic disease and iron deficiency anemia: diagnostic and therapeutic implications. Blood. 2009 ; 113: 5277-5286
6. Ganz T. Hepcidin and its role in regulating systemic iron metabolism. Hematology Am Soc Hematol Educ Program. 2006 ;: 29 507-35
7. Mcgrath H, Rigby PG. Hepcidin: inflammation's iron curtain. Rheumatology. 2004 ; 43: 1323-1325 (Pubitemid 39480917)
8. Wrighting DM, Andrews NC. Interleukin-6 induces hepcidin expression through STAT3. Blood. 2006 ; 108: 3204-3209
9. Ershler WB, Keller ET. Age-associated increased interleukin-6 gene expression, late-life diseases, and frailty. Annu Rev Med. 2000 ; 51: 245-270 (Pubitemid 30216036)
10. Calabro P, Willerson JT, Yeh ET. Inflammatory cytokines stimulated C-reactive protein production by human coronary artery smooth muscle cells. Circulation. 2003 ; 108: 1930-1932 (Pubitemid 37296536)
11. Emery P, Keystone E, Tony HP, et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. Ann Rheum Dis. 2008 ; 67: 1516-1523
12. Ridker PM, Rifai N, Pfeffer MA, Sacks F, Braunwald E. Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators. Circulation. 1999 ; 100: 230-235 (Pubitemid 29340127)
13. Albert MA, Danielson E, Rifai N, Ridker PM. Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. JAMA. 2001 ; 286: 64-70 (Pubitemid 32606333)
14. Arnaud C, Burger F, Steffens S, et al. Statins reduce interleukin-6-induced C-reactive protein in human hepatocytes: new evidence for direct antiinflammatory effects of statins. Arterioscler Thromb Vasc Biol. 2005 ; 25: 1231-1236 (Pubitemid 40776614)
15. Arabul M, Gullulu M, Yilmaz Y, et al. Effect of fluvastatin on serum prohepcidin levels in patients with end-stage renal disease. Clin Biochem. 2008 ; 41: 1055-1058
16. Ridker PM. Rosuvastatin in the primary prevention of cardiovascular disease among patients with low levels of low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: rationale and design of the JUPITER trial. Circulation. 2003 ; 108: 2292-2297 (Pubitemid 37413531)
17. Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008 ; 359: 2195-2207
18. Ridker PM, Danielson E, Fonseca FAH, et al. Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. Lancet. 2009 ; 373: 1175-1182
19. Glynn RJ, Danielson E, Fonseca FA, et al. A randomized trial of rosuvastatin in the prevention of venous thromboembolism. N Engl J Med. 2009 ; 360: 1851-1861
20. Blanc B, Finch CA, Herbert V, et al Nutritional Anaemias: Report of a WHO Scientific Group. Geneva: World Health Organization ; 1968 :
21. Means RT. Recent developments in the anemia of chronic disease. Curr Hematol Rep. 2003 ; 2: 116-121